In the quest for therapy for diffuse large B cell lymphoma (DLBCL), Kendrick et al. (2017) proposed an innovative strategy to simultaneously use GQC-05 and IMC-76 (8,Figure 2), which respectively recognize the Myc G4 and the Bcl-2 i-motif. Here, MYC is linked to diffuse large B-cell lymphoma.